BRCA1

Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity.

Cancer de l'ovaire de haut grade — classification des variants BRCA1/BRCA2

Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity

Cancer de l'ovaire héréditaire — classification des variants *BRCA1/2*

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial

Cancer du sein de stade III HER2-négatif avec déficit HRD / mutation germinale *BRCA1/2*

Constitutional BRCA1 promoter methylation as a biomarker for ovarian cancer risk.

Prédisposition héréditaire au cancer de l'ovaire / épimutatation constitutionnelle BRCA1

Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers: a meta-analysis

Cancer du sein controlatéral chez les porteuses de variants pathogènes BRCA1/2, PALB2, CHEK2, ATM

Decoding BRCA1 and BRCA2 Mutations in High-Grade Serous Ovarian Cancer: Impact on Prognosis, Platinum Response, and Actionability

Cancer de l'ovaire séreux de haut grade germinal BRCA1/2 — impact pronostique selon la topographie des variants

Assessing the Clinical Relevance of BRCA1 RING Domain Variants of Uncertain Significance.

Cancer du sein et de l'ovaire héréditaire (HBOC)

Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C

Cancer de l'ovaire *BRCA1*-déficient — métastase

Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Participants

Dépistage opportuniste BRCA1, BRCA2 et PALB2 en biobanque hospitalière finlandaise

HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.

Cancer tubo-ovarien — stratification HRD et implications PARP inhibiteurs

Two decades of PARP inhibitor synthetic lethality in cancer.

Prédisposition héréditaire aux cancers du sein, de l'ovaire, de la prostate et du pancréas liés à BRCA1/BRCA2 — inhibiteurs PARP comme biomarqueur thérapeutique germinal

Ultra-rare functional variants reveal early-onset breast cancer risk genes and pathways in the UK Biobank and All of Us Research Program.

Cancer du sein à début précoce — variants germinaux ultra-rares dans des gènes et voies de prédisposition

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer

Cancer du sein héréditaire (HBOC) chez les jeunes patientes (≤40 ans)

PRS-BC313 integration for tailored breast cancer prevention in female patients and their healthy relatives

Prévention personnalisée du cancer du sein chez les porteuses de variants HBOC (PRS-BC313 + modèle CanRisk)

The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Porteuses *BRCA1/2* — communication du risque et décision de prise en charge

BRCA1 c.68_69del as a founder variant in the Spanish Roma: prevalence and screening implications

Cancer du sein et de l'ovaire héréditaire — variant fondateur *BRCA1* dans la population Rom espagnole

Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer

Cancer du sein de la femme jeune (≤40 ans) — prédisposition germinale

Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer

Cancer du sein et de l'ovaire héréditaire — double hétérozygotie

Damaging missense variants in innate immunity genes are associated with earlier age of breast cancer onset in BRCA1 185delAG carriers

Modificateurs de pénétrance du cancer du sein chez les porteuses *BRCA1* 185delAG

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: real-world multicenter data

Cancer du sein triple négatif précoce germinal BRCA1/2 — réponse au pembrolizumab néoadjuvant + chimiothérapie

Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.

Cancer du sein précoce chez les porteuses BRCA1/2 — radiothérapie vs mastectomie

Germline Pathogenic Variants in Breast Cancer-Predisposing Genes Among Early-Onset Female and Male Breast Cancer in Ethiopia.

Cancer du sein héréditaire à début précoce (Éthiopie)

Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers

HBOC — Cancer du sein héréditaire (prévention primaire)

Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations

Cancer du sein héréditaire — définition du panel de mainstreaming en oncologie courante

ACT-ON: Assisted cascade testing via outreach and navigation - Real-world experience with clinician-initiated, third-party-facilitated family cascade testing

Prédisposition héréditaire au cancer — implémentation du cascade testing

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.

Cancer du sein HER2-négatif localement avancé ou métastatique chez les porteuses BRCA

A Decade of Hereditary Cancer Genetic Testing Results in Asian Indian population: Retrospective Study.

Cancers héréditaires, cohorte indienne

VAF-tumor content graph: a simple visual framework for interpreting hereditary cancer variants and supporting genetic counseling in tumor-only sequencing.

Interprétation des variants de prédisposition en séquençage tumoral seul

Association of high and moderate penetrance monogenic variants, polygenic risk, and family history with breast cancer in an ancestrally diverse population.

Cancer du sein — intégration variants monogéniques + score polygénique + histoire familiale en population diverse

Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada.

Mastectomie prophylactique BRCA1/2 et PALB2 — impact de l'ethnicité sur l'adhésion

Epithelial mesenchymal transition initiates precancer states in BRCA1 mutation carriers.

Porteurs germinaux BRCA1 — états précancéreux mammaires et susceptibilité à la transition épithélio-mésenchymateuse

Prevalence of BRCA1 and BRCA2 Variants in an Unselected Population of Women With Breast Cancer

Cancer du sein — prévalence et disparités ethniques des variants BRCA1/2

Genomic alterations enable BRCA1 methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancer

Carcinome séreux de haut grade de l'ovaire

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Cancer de l'ovaire récidivant — réponse exceptionnelle aux inhibiteurs PARP

Targeted BRCA1/BRCA2 Sequencing in a Bangladeshi Clinically Referred Cohort Identifies Candidate BRCA1 Loss-of-Function Variants and a Multi-Exon Deletion-Like CNV Signal

Cancer du sein et de l'ovaire héréditaire (HBOC) — population bangladaise

Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: a 5 Ws and 2 Hs practitioner toolkit.

Ménopause chirurgicale précoce après salpingo-ovariectomie de réduction de risque chez les porteuses BRCA